Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus PROBAMPACIN.
PIPERACILLIN AND TAZOBACTAM vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination
Penicillin Antibiotic